Clinical Trial VICCHEM1096


A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Principal Investigator(s)

Stephen Strickland


  • Protocol No. VICCHEM1096
  • Open Date: 10/24/2011
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: The primary objective is to compare the overall survival between Arm A and Arm C and between Arm B and Arm C.
  • Disease Sites: Leukemia
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Decitabine; Sapacitabine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01303796
  • Secondary Protocol No: CYC682-12



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.